Group I introns are pre-mRNA introns that do not require the spliceosome for their removal. Instead, they fold into complex three-dimensional structures and catalyze two transesterification reactions, thereby excising themselves and joining the flanking exons. These catalytic RNAs (ribozymes) have been modified previously to work in trans, whereby the ribozymes can recognize a splice site on a substrate RNA and replace the 59-or 39-portion of the substrate. Here we describe a new variant of the group I intron ribozyme from Tetrahymena that recognizes two splice sites on a substrate RNA, removes the intron sequences between the splice sites, and joins the flanking exons, analogous to the action of the spliceosome. This 'group I spliceozyme' functions in vitro and in vivo, and it is able to mediate a growth phenotype in E. coli cells. The intron sequences of the target pre-mRNAs are constrained near the splice sites but can carry a wide range of sequences in their interior. Because the splice site recognition sequences can be adjusted to different splice sites, the spliceozyme may have the potential for wide applications as tool in research and therapy.
Introduction
Group I introns are intervening sequences in pre-mRNAs that do not require the spliceosome for their removal [1] . Instead, they fold into three-dimensional structures and catalyze two transphosphorylation reactions resulting in their excision from the primary transcript and the joining of their flanking exons [1, 2, 3] . The biochemistry of group I intron ribozymes has been studied extensively (for review, see [4, 5] ) and crystal structures have been reported for group I introns from three different species [6, 7, 8] .
Group I intron ribozymes have been engineered to catalyze several non-native reactions. For example, they can be converted from the natural cis-splicing format into a trans-splicing format, by removing the ribozyme 59-exon and replacing it with a short substrate recognition sequence [9, 10] . This substrate recognition sequence base pairs to a complementary target site on the substrate RNA, thereby specifying the splice site [11, 12] . In the subsequent reaction, the ribozyme replaces the 39-portion of the substrate RNA with its own 39-exon; this has been demonstrated in vitro and in bacterial and mammalian cells [10, 13, 14] . In addition to replacing the substrate 39-portion by the ribozyme 39exon, group I intron ribozymes are also able to replace the substrate 59-portion by the ribozyme 59-exon. In this case, the recognition of the splice site is more complicated, using the concerted action of the ribozyme 59-terminus and 39-terminus [15, 16] .
When the two types of reactions -replacement of the substrate 39-and 59-portion -are combined, group I intron ribozymes can facilitate trans-excision reactions -the removal of an internal RNA segment and the joining of the flanking exons [17] . This trans-excision reaction relies upon three recognition sequences, consisting of the formation of the P1, P9.0, and P10 helices between substrate and ribozyme [16, 18] . These trans-excision ribozymes were shown to excise fragments of up to 28 nucleotides from short substrates in vitro [17] , and remove single nucleotides from fulllength mRNA in E. coli cells [19] . No evidence has indicated that longer fragments can be excised in cells. To obtain ribozymes that can efficiently excise long internal substrate fragments from full length mRNAs under physiological conditions, a different splice site recognition principle was used here to recognize the 59-splice site and the 39-splice site with two separate structural elements, the P1 and P9.2 helix, respectively.
Here we demonstrate that a new variant of the group I intron from Tetrahymena can remove introns from a full-length mRNA in trans. The ribozyme differs from the described trans-excision ribozymes by using its 39-terminal P9.2 helix for recognition of the 39-splice site (Figure 1) , which leads to the efficient excision of introns with a length of 100 nucleotides. The excision is accurate in vitro and in E. coli cells, and tolerates many sequences within the intron. We termed this RNA 'spliceozyme' because it is a ribozyme that functions like a spliceosome. After further developments, the spliceozyme may serve as a versatile tool to remove internal RNA sequences for applications in research and in therapy.
Results

Design of the Spliceozyme
The spliceozyme described here is based on the group I intron ribozyme from Tetrahymena (Figure 1 ). For recognition of the 59-splice site, the substrate sequence immediately adjacent to the splice site was recognized by forming the P1 helix and the P1 extension helix, followed by an internal loop and a duplex at the ribozyme 59-terminus [12, 13, 20, 21] . The ribozyme design with only a P1 duplex was labeled P1; the design with a P1 duplex and a P1 extension was labeled P1ex, and the design that included all elements of the extended guide sequence (P1 helix, P1 extension, internal loop, and 59-duplex) was labeled EGS. For recognition of the substrate 39-splice site, the P9.2 helix was designed to form in trans, and was truncated to 9 base pairs. The substrate for the trans-splicing reactions described here was the 678-nucleotide long mRNA encoding the enzyme chloramphenicol acetyl transferase (CAT), with an intron of 64 or 100 nucleotides in length inserted at position 258.
Spliceozyme activity in vitro
To test whether the spliceozyme could function in vitro, the CAT pre-mRNA was radiolabeled internally and incubated with spliceozymes targeting the two exon/intron junctions of a 100nucleotide long intron. Reaction conditions used near-physiological conditions, including 5 mM MgCl 2 at 37uC, 100 nM CAT pre-mRNA, and spliceozyme concentrations of 100 nM and 1 mM. Splicing products of the correct size were detectable after only a few minutes of reaction time (Figure 2 , upper panels). Quantitation of the signals showed that within five minutes, 3-7% and 23-36% of the pre-mRNA were converted to a splicing product of the correct size by 100 nM and 1 mM spliceozyme, respectively (Figure 2 , lower panels). The ribozyme with a P1 59terminus reacted approximately 2.5-fold faster than the other ribozymes (0.25 min 21 versus 0.09-0.12 min 21 , respectively), each with a P9.2 duplex length of 9 base pairs (compare Figures 2A, B , and C). This suggests a possible inhibitory role of extensions at the 59-terminus in the P1ex and EGS constructs, and is consistent a previous suggestion that the ribozyme 59-structure could indeed be partially inhibitory for trans-splicing [22] .
To determine if the products contained the correct splicing junction, the reaction products were subjected to RT-PCR, specifically amplifying sequences that contained both the 59-exon and the 39-exon of the CAT mRNA. Cloning and sequencing showed the correct exon junction sequence in ten out of ten transsplicing products (data not shown). These results demonstrated that a spliceozyme using its 59-terminus for recognition of the 59splice site and its 39-terminus for recognition of the 39-splice site via formation of the P9.2 helix was able to efficiently and accurately remove the intron from a pre-mRNA in vitro.
Between 8% and 46% of the substrate molecules lost their 59exon and were thereby converted to side products within one hour ( Figure S1A ). The differences were correlated with two factors: spliceozyme concentration and design of the spliceozyme 59terminus. First, a spliceozyme concentration of 1 mM led to approximately 4-fold greater release of the 59-exon compared to the same constructs at a ribozyme concentration of 100 nM, likely a result of more reaction events generating more side reaction events. Second, in constructs differing in the ribozyme 59-terminus (all with a P9.2 duplex length of 9 base pairs) approximately twofold higher 59-exon release was observed in the absence of a P1 extension duplex (construct P1) compared to the other two constructs that contained a P1 extension duplex (P1ex, EGS). One possible explanation for this behavior is that the ribozyme 59terminus forming the P1 extension helps position the 39-splice site at the catalytic site by forming the P10 helix [23] ; this helix formation may therefore shorten the time between the first and the second catalytic step of splicing, during which the 59-exon can escape from the spliceozyme. At 1 mM spliceozyme concentration additional side products are detectable in Figure 2 ; the identity of the corresponding side products is currently unclear. The 59-terminus of the intron is capped by an exogenous G (black) and the 39-terminus of the intron is liberated. The sequences correspond to the removal of an intron from splice site 258 of the CAT pre-mRNA used in this study. The internal sequence of the intron is drawn as a bold blue line. Note that a hairpin terminator is added to the 39-terminus for all reactions in cells. The secondary structure of the ribozyme is based on [58] with the alteration that the P4-P6 domain was positioned on the right side for clarity. doi:10.1371/journal.pone.0101932.g001
Influence of the P9.2 duplex length on spliceozyme activity in vitro
Truncation of the P9.2 helix from 9 base pairs to 8, 7, or 6 base pairs did not significantly affect spliceozyme efficiency ( Figure 3A ). Only when the length of the P9.2 helix was reduced to 5 base pairs was a lower fraction of substrate converted to product than ribozymes with a P9.2 helix of six to nine base pairs (31% versus 45%-58%, respectively). This is consistent with the finding that duplexes shorter than 7 base pairs are below the optimal length for the specific recognition of target sites [24] . The length of the P9.2 duplex did not strongly influence the amount of 59-exon release ( Figure S1B ).
To estimate the effect of truncating the P9.2 helix on splicing accuracy, ten splice site junctions were determined by reverse transcription, cloning and sequencing of the splicing products resulting from a P1 helix of 6 base pairs and a P9.2 helix with 5 base pairs ( Figure 3B ). Nine out of ten splice site junctions had the correct sequence. One sequence gave evidence for an event of aberrant splicing, in which the guanosine four nucleotides downstream of the correct guanosine was chosen as 39-splice site. In contrast, ten out of ten sequences showed the correct product Figure 1 ). The corresponding constructs are labeled as 59 P1, 59 P1ex, and 59 EGS, respectively. The top panels show autoradiograms of internally radiolabeled splicing products after separation by denaturing polyacrylamide gel electrophoresis. The marker (M) shows the position of pre-mRNA (778 nt), mRNA (678 nt), and 59-exon (278 nt). The 39-exon and the intron had a length of 400 nt and 100 nt, respectively. For each spliceozyme construct, two splicing reactions are analyzed with spliceozyme concentrations of 100 nM and 1 mM. Samples were taken at reaction times between 0 and 60 minutes. A schematic of the substrates and reaction products is shown to the right of the image, with exons in red and the intron in blue. Bottom panels show the quantitation of the disappearance of the CAT pre-mRNA (triangles) and the appearance of the CAT mRNA (squares). Empty symbols correspond to 100 nM spliceozyme, while filled symbols correspond to 1 mM spliceozyme concentration. Grey lines show single-exponential curve fits to the products and double-exponential curve fits to the reaction products. Error bars are standard deviations from three experiments. doi:10.1371/journal.pone.0101932.g002 when the 39-splice site was recognized by a 9 base pair helix (data not shown). This suggested that a P9.2 duplex length of 5 base pairs may be too short for reliable recognition of the correct 39splice site, consistent with earlier considerations on substrate recognition helices [24] . Together, the truncation experiments at the ribozyme 59-and 39-terminus suggested that a P1 extension at the 59-splice site reduced the loss of 59-exons, and that the 39-splice site required a P9.2 duplex with at least 6 base pairs.
Spliceozyme activity in cells
To assess the activity of the spliceozyme in cells, a plasmid encoding the spliceozyme and a CAT pre-mRNA with a 64nucleotide long intron was generated, and transformed into E.coli cells ( Figure 4A ). In order for bacterial resistance to chloramphenicol to be conferred, it is necessary for the spliceozyme in the cells to process CAT pre-mRNA to CAT mRNA, which is then translated to the CAT enzyme. The CAT enzyme acetylates chloramphenicol with acetyl-coA as acetyl donor [25] , rendering chloramphenicol unable to inhibit the ribosome [26] , thereby allowing E. coli cells to grow in the presence of chloramphenicol. Indeed, E.coli cells transformed with the spliceozyme construct were able to grow on medium containing 8 mg/mL chloramphenicol ( Figure 4B ; grey columns), at levels similar to the growth mediated by CAT mRNA without an intron ( Figure 4B , black column on the left). To test whether this growth was a result of spliceozyme-mediated catalysis, the catalytic center of the spliceozyme was inactivated by mutations. A mutation at the guanosine binding site (G264A) was found previously to strongly reduce ribozyme activity while maintaining the overall ribozyme fold [27, 28, 29] . Because the remaining weak activity appeared to generate some bacterial growth (data not shown) the ribozyme was further inactivated with a total of six mutations (A261U, C262A, A263G, G264A, A265U, and C266A). The modified construct did not mediate detectable bacterial growth ( Figure 4B , white columns) above the background level of the assay ( Figure 4B , black column on the right), approximately 1/1,000 of the signal from the functional spliceozyme. Two different introns in the pre-mRNA resulted in similar levels of growth with active spliceozyme and no growth with inactive spliceozyme (constructs 64-SiC2 and 64-SiC3; Figure 4B ). Note that these two intron sequences were not arbitrarily chosen but were the result of a selection (see below). To estimate the splicing accuracy of the spliceozyme in cells total RNA was isolated and used to determine the sequence of splice junctions in the CAT mRNA as described for the in vitro reaction. Ten out of ten trans-splicing products had the correct sequence (data not shown). These results demonstrated that catalysis by the spliceozyme removed the intron from a pre-mRNA in E. coli cells, and did so accurately and efficiently enough to generate an antibiotic resistance phenotype. Note that the wild type sequence (WT) differs from the splicing products in three silent mutations (empty triangles), which confirmed that the sequences were splicing products and not a contamination by the wild type gene. Nine out of ten sequences showed the sequence expected from correct splicing at the 39-terminal G, whereas one sequence indicated that the guanosine four nucleotides downstream of the intended 39-splice site was used instead. The sequence participating in the P1 helix is underlined, containing the 59-splice site (filled triangle). doi:10.1371/journal.pone.0101932.g003 coli cell growth on LB-agar plates containing 8 mg/mL chloramphenicol, by measuring the A 600 of cell suspensions from washing the plates after incubation. The black column on the left shows the A 600 from cells that express the wild type CAT gene without intron. Grey columns denote the A 600 resulting from plasmids containing a CAT gene with an intron and wild-type spliceozymes. White columns denote the A 600 from the same constructs as in the grey columns but with six mutations in the catalytic core of the spliceozymes. The black column on the right denotes the A 600 resulting from cells containing the pUC19 plasmid without spliceozyme or CAT gene. Two different intron sequences with a length of 64 nucleotides were inserted into plasmid pUCSz2 for this assay (64-CiC2 and 64-SiC3; note that both of these introns were selected for their efficient removal by the spliceozyme; see materials and methods). Note the logarithmic scale for the A 600 . Error bars are standard deviations from three biological samples. doi:10.1371/journal.pone.0101932.g004
Sequence requirements of the intron
To determine whether the spliceozyme required specific sequences within the intron of the CAT pre-mRNA, two selection experiments were performed with a 100-nucleotide long intron. In the first selection experiment, the internal region of the intron between the substrate recognition sequences was randomized (N 64 ; Figure 5A ; clone names contain an i for 'internal'). A library of plasmid constructs was generated that was identical to the construct described above but differed in the length of the intron (100 nucleotides) and the randomization of the 64 internal nucleotides of the intron sequences. E. coli cells were then transformed with this plasmid library. Ten randomly chosen clones from this E. coli library were tested for growth on LB plates with chloramphenicol (10 mg/mL). Eight out of ten clones mediated detectable growth, and three of them mediated moderate growth ( Figure 5B , white columns; clone names contain an L for 'library') with efficiencies similar to an additional ten clones that were selected from the library for efficient growth on LB-chloramphenicol medium ( Figure 5B , grey columns; clone names contain an S for 'selected'). When the sequences of all 20 introns were correlated with the mediated chloramphenicol resistance, no sequence pattern could be identified that was associated with increased activity, based on a comparison of their sequences, predicted secondary structures, and predicted selffolding energies [30] ( Figure 5C ). A similar selection was performed with a 64-nucleotide long intron containing a The resulting A 600 is given for 20 clones, ten of which were chosen before selection on LB-chloramphenicol plates (white columns), and ten of which were chosen after this selection step (grey columns). The name of each clone is given below, with 'L' indicating clones from the unselected library and 'S' indicating selected clones, 100 denoting the length of the intron, the letter i indicating that the internal region of the intron was randomized, and the number after 'C' denoting the clone number. Error bars are standard deviations from three experiments. (C) Sequences of 20 cloned intron sequences, sorted according to their activity in cells. The left column lists the clone names, using the same nomenclature as in (B). The middle column shows the internal sequence of that clone that resulted from the N 64 library, which was inserted between the constant regions of the intron (see (A)). The right column shows the growth activity, measured as A 600 of cell suspensions that resulted from washing LB-growth plates containing chloramphenicol, relative to growth on medium without chloramphenicol. doi:10.1371/journal.pone.0101932.g005 randomized sequence of 28 nucleotides. This experiment also gave rise to highly efficient introns, and similarly did not reveal favored patterns for the intron sequences (data not shown). Although neither of these experiments covered the complete sequence space of the randomized N 64 and N 28 sequences, this was not necessary to estimate the frequency of beneficial intron sequences within random libraries. The results revealed that the spliceozyme efficiency varied significantly with the internal sequence of the pre-mRNA intron, and that approximately 30% of sequences from a random library constituted a favorable internal intron sequence for processing by the spliceozyme.
The second selection experiment with an intron of 100 nucleotides tested the sequence requirement for the ten nucleotides between the 39-splice site and the P9.2 helix (N 10 ; Figure 6A ). These ten nucleotides were randomized similar to the previous selection, and the corresponding plasmid library was transformed into E.coli cells. When ten randomly chosen clones from this E.coli library were tested for growth on medium containing 10 mg/mL chloramphenicol, none showed detectable growth ( Figure 6B , clone names contain an L for 'library'). Growth was also measured for ten clones selected from the small fraction of the library that mediated growth on LB-chloramphenicol medium ( Figure 6B , clone names contain an S for 'selected'). When the sequences of these clones were sorted according to the level of mediated growth a correlation between splicing activity and the identity of nucleotides 1, 2, and 10 within this region became apparent ( Figure 6B, right) . The five most efficient sequences ( Figure 6B , column graph) were used to characterize the sequence requirement in this region. At position 1, four of these five sequences carried a U, consistent with the wild type ribozyme sequence (compared to 3/10 sequences from the selected library). At position 2, all five sequences carried a G, consistent with the wild type, and in contrast to the pre-selected pool (4/10 sequences). This is consistent with the role of nucleotide 2 in base pairing to a C adjacent to the P9.0 helix [31] in the wild type ribozyme. At position 10, all active sequences carried a C or a U, consistent with the wild type C, and different from the pre-selected pool (6/10 sequences). This is consistent with the role of nucleotides 9 and 10 in forming the P9.0 helix [32, 33, 34] . At position 9, the presence of four U's in the 7 most active clones would be consistent with a weak selection at this position. No significant enrichment was observed at other positions. Together, these results suggested that the 10-nucleotide sequence between the P9.2 helix and the 39splice site was constrained to specific nucleotides in at least 3 positions.
Efficiency of the spliceozyme in cells
To obtain a measure for the efficiency of the spliceozyme in E. coli cells the amount of active CAT enzyme in E. coli cell extract, the formation of which requires the correct processing of CAT pre-mRNA, was quantified ( Figure 7A ). CAT activity was measured by an assay utilizing Acetyl-CoA and DTNB (5,5-Dithio-bis(2nitrobenzoic acid)) [35] . Four constructs expressing spliceozyme and CAT pre-mRNA with introns that had previously mediated efficient growth on chloramphenicol containing medium resulted in CAT levels between 0.004 and 0.010 units of CAT per OD 600 of cells (grey columns). This corresponded to 3.3% and 7.2% of the activity generated by a construct expressing CAT mRNA without an intron, in the absence of spliceozyme expression (0.13 units of CAT per OD 600 of cells; black column on the right). In contrast, three constructs expressing spliceozyme and CAT pre-mRNA introns that mediated only poor growth or no growth showed significantly lower CAT activity in the bacterial extract (white columns). This confirmed that spliceozyme-facilitated CAT activity mediated the bacterial chloramphenicol resistance observed in the previous experiments.
To test whether the variation in CAT activity between different intron sequences was mediated by changes in the CAT pre- The clone name is given on the left, the growth on LB-agar plates containing chloramphenicol is shown as horizontal columns, and the N 10 sequence is given on the right. Clone names containing 'L' indicate the unselected library, while 'S' indicates a selection step with chloramphenicol. The letter 'j' denotes that the randomized region is located near the 39-terminus of the CAT mRNA intron. The growth was measured on plates containing 10 mg/mL chloramphenicol and normalized to growth on medium without chloramphenicol. The sequence at the top (WT) corresponds to the wild type sequence of the Tetrahymena ribozyme. Nucleotides that are identical with the wild type sequence are colored in blue. The position 10 tolerates a U, which is consistent with its base-pairing role, and is colored in red. Errors are standard deviations from three experiments. doi:10.1371/journal.pone.0101932.g006 mRNA/mRNA expression level, total RNA was isolated from each of the bacterial constructs, and CAT pre-mRNA/mRNA 39exons were quantified by RT-qPCR ( Figure 7B ). Resulting 39exon levels indicated that RNA expression levels were not higher for efficient introns (grey columns) than for inefficient introns (white columns), thereby excluding the possibility that the CAT activity differences were caused by differences in the CAT RNA expression levels. Similarly, plasmid expression levels ( Figure 7C ) of efficient introns (grey columns) were not higher than those of inefficient introns (white columns), excluding the possibility that these introns acted by affecting the plasmid copy numbers. It is interesting to note that the lowest plasmid copy number was observed with pUC19 (no expression of pre-mRNA or spliceozyme), with a slightly higher expression for the construct that expressed the CAT mRNA, and even higher copy numbers for plasmids that expressed both CAT pre-mRNA and spliceozyme. This finding, however, does not affect the conclusion regarding modulation of plasmid copy numbers or RNA expression levels the CAT pre-mRNA intron sequences.
Together, these results confirm that catalytic activity of the spliceozymes mediated bacterial resistance to chloramphenicol by processing CAT pre-mRNA to CAT mRNA, thereby facilitating the translation of active CAT enzyme in bacterial cells. Future improvements may result in spliceozymes that process a larger portion of substrate RNAs, and with less intron sequence dependence, for possible uses as tools in research and therapy.
Discussion
In this study we demonstrated that variants of the Tetrahymena group I intron ribozyme can remove introns in trans from pre-mRNAs by using their 59-terminus and 39-terminal P9.2 helix for recognition of 59-and 39-splice sites, respectively. These spliceozymes can accurately remove 100-nucleotide long introns from a pre-mRNA, in vitro and in E. coli cells, thereby facilitating the expression of functional protein and mediating an antibiotic resistance phenotype. The spliceozymes require specific recognition sequences near the 59-and 39-splice sites but tolerate many sequences in the internal region of the intron.
Two short substrate recognition elements in the spliceozyme of five to nine base pairs were sufficient to specify the location of pre-mRNA splicing in E. coli cells despite the fact that in principle, any uridylate residue among the many RNAs in E.coli cells that is flanked by the complementary sequences could serve as substrate [11, 12] . This observation, however, is consistent with the finding that only a small fraction of all possible splice sites can be used efficiently by trans-splicing ribozymes. This fraction is in the range of ,3% for the CAT mRNA, as estimated by the computation of the total free energy of substrate binding, a good predictor of splice site efficiency [22] . The fraction of efficient splice sites in a cellular environment may be even lower for highly structured and chemically modified RNAs such as the ribosome and tRNAs, which constitute the bulk of cellular RNAs. The precise frequency of off-target effects with the spliceozymes is currently unclear.
Quantitation of CAT activity in E. coli cell extract suggested that approximately 5% of the CAT pre-mRNA were converted to functional CAT mRNA by the spliceozyme, when compared to CAT mRNA lacking an intron ( Figure 7A ). This efficiency is similar to the estimated 3-4% of CAT mRNA repaired in a similar . Grey columns show the CAT activity of constructs expressing a spliceozyme and a CAT pre-mRNA containing an intron that mediated efficient bacterial resistance to chloramphenicol. White columns show the CAT activity mediated by introns that led to poor or no bacterial resistance to chloramphenicol. Construct names starting with 64 or 100 label the length of the intron in the CAT pre-mRNA gene, 'S' denotes that the clone was selected for activity on medium with chloramphenicol, 'L' denotes that the clone was chosen from an un-selected library, 'I' denotes that the library for this selection was randomized in the internal region of the intron, and the number after C is the clone number. CAT WT denotes a construct without spliceozyme, and in which the CAT gene did not contain an intron, resulting in 0.1360.01 units of CAT activity per OD 600 . The percent of CAT activity relative to the CAT WT construct is noted above each column. (B) Level of CAT RNAs estimated by RT-qPCR of the CAT RNA 39exon. This assay measures the sum of CAT pre-mRNA and CAT mRNA. (C) Molar amount of plasmid isolated from logarithmically growing E. coli cells. Note that the unit OD 600 is used as an absolute value, corresponding to the cells in a volume of 1 mL cell suspension with OD 600 = 1. For all graphs shown in Figure 7 , error bars denote standard deviations from three biological replicates. doi:10.1371/journal.pone.0101932.g007
bacterial system by a trans-splicing group I intron using only a single splice site [21, 36] . This suggests that the spliceozymes described in this study were similarly efficient as the previously used trans-splicing ribozymes.
Spliceozymes could potentially be employed for several applications in research and therapy. Research applications could include the use of spliceozymes to create and study different splicing isoforms and phenomena such as alternative splicing, exon skipping, or recursive splicing [37, 38, 39, 40] . Spliceozymes could also be used to model specific biochemical steps in the evolution of the spliceosome, which likely originated from a common ancestor with group II intron ribozymes [41, 42, 43, 44, 45, 46] . It is currently unclear how the spliceosome recruited proteins during its evolution, fragmented into multiple RNAs, and developed multiple turnover reactions. The current spliceozyme could therefore serve as a model system to study analogous steps in the evolution from a ribozyme to a dynamic RNP.
Spliceozymes may also have applications in therapy, for example in the correction of aberrant splicing. At least 10% but perhaps 60% of all disease-causing genetic mutations result in aberrant splicing [47, 48, 49] . It may be possible to use spliceozymes for the treatment of these genetic disorders by processing incompletely or incorrectly spliced pre-mRNAs to functional mRNAs. The procedure for this approach would be similar to that envisioned for trans-splicing ribozymes for the replacement of RNA 39-portions in human cells [13, 50, 51, 52, 53, 54, 55] . For this application to be feasible it would first be necessary to improve the delivery (or in situ expression) of spliceozymes, their efficiency in cells, and minimize potential off-target splicing effects [10, 13, 21, 51, 56] .
Materials and Methods
Construction of spliceozyme/CAT pre-mRNA expression plasmids
The plasmid expressing the spliceozyme and the CAT pre-mRNA ( Figure 3A) was based on the previously described pUC19based expression system [21] , which includes a multiple cloning site with SacI, BamHI, SphI and HindIII. The ribozyme expression cassette was inserted between restriction sites SacI and BamHI, and the CAT expression cassette between SphI and HindIII, in three steps. First, the CAT gene was PCR amplified from the plasmid pLysS (Novagen) as described [21] , and prepared for the insertion of an intron at position 258 by introducing three restriction sites through PCR mutagenesis. Specifically, the 39-PCR primer for amplifying the 59-exon of the CAT gene introduced the silent mutations G243A and G246A to generate a SpeI restriction site, and added a 39-terminal XmaI site near position 258. The 59-PCR primer for amplifying the 39-exon introduced the silent mutation T264A to generate the BsrGI site, and added a 59-terminal XmaI site near position 258. The PCR products of the two exons were digested with SphI and XmaI (59exon) and HindIII and XmaI (39-exon), then both fragments were ligated into the SphI/HindIII cassette of pUC19b [21] to create plasmid pUCSz1. The sequence with the silent mutations is visible in the sequence of the correctly spliced products ( Figure 6B) .
Second, the spliceozyme cassette, including the trc2 promoter [57] and a hairpin terminator, was generated in successive PCR reactions analogous to another trans-splicing ribozyme [21] . By successively modifying the 59-terminus of the Tetrahymena group I intron gene with 59-PCR primers, the ribozyme 59-recognition sequence was adjusted to the new splice site 258 (see Figure 1A) , and the trc2 promoter and a BamHI restriction site were added. By successively modifying the 39-terminus by 39-PCR primers, the 39-end of the spliceozyme was truncated (see Figure 1A ), a hairpin terminator (59-GCATAACCCCTTGGGGCCTCTAAACGGG-TCTTGAGGGGTTTTTTG-39; stem underlined) was added, and a SacI restriction site was added. The PCR products were then cloned into the BamHI -SacI sites of pUCSz1 to generate pUCSz2.
Third, the intron sequences were inserted into pUCSz2 using the SpeI and BsrGI restriction sites introduced into the CAT sequence. Oligonucleotides 59-gaactagtgatatgggat AGTGTTCA-CTAGAAGG -N 28 -GATTAGTTTTGGAGTACTCG agtgtacacc-39 and 59-gaactagtgatatgggat AGTGTTCACTAGAAGG -N 64 -GATTAGTTTTGGAGTACTCG agtgtacacc-39 were converted to double strands by PCR, digested with SpeI and BsrGI, and inserted into the corresponding sites of pUCSz2 (exon sequences are in lower case, intron sequences in upper case, restriction sites are underlined). This created introns with a total length of 64 and 100 nucleotides, and randomized regions of 28 and 64 nucleotides, respectively. These two plasmid libraries were used in selections for efficient internal intron sequences.
For the selection of intron sequences between the P9.2 helix and the 39-terminal guanosine (G414), plasmid libraries with ten randomized nucleotides were generated by PCR amplification with a primer that carried the randomized sequence. As PCR template, a clone with an intron length of 100 nucleotides (100-SiC10, Figure 5C ) was used. The 39-PCR primer (59-ccttgtacactc -N 10 -AAACTAATCTGCAAGGGGAG-39) randomized the region of interest, and added the BsrGI site (underlined). All other steps were analogous to the selection of internal intron sequences.
Mutagenic inactivation of the spliceozyme at positions 261-266 was completed by site-directed mutagenesis, using two oligonucleotides that covered 19 bases on each flank of the mutated sequence. The resulting mutations were A261U, C262A, A263G, G264A, A265U, and C266A. The procedure used PrimeSTAR GXL DNA Polymerase (Invitrogen) and the QuickChange TM sitedirected mutagenesis protocol developed by Stratagene (La Jolla, CA).
Selection of efficient intron sequences
Plasmid libraries containing partially randomized introns were transformed into electrocompetent E. coli DH5a cells, and the cells were plated onto LB-agar containing 100 mg/mL ampicillin. After incubation at 37uC for 16 hours, the plates were washed with LB medium to generate the bacterial libraries, which could be frozen as glycerol stocks. Bacterial libraries were diluted to an A 600 of 0.015 with liquid LB medium, and induced with 1 mM IPTG by shaking for 1 hour at 37uC. For the selective step, 100 mL of this culture were plated onto LB-agar plates containing chloramphenicol of the noted concentration, and allowed to grow for 16 hours at 37uC. Individual colonies were selected and analyzed for the sequences and efficiencies of individual introns.
Spliceozymes and pre-mRNAs for in vitro reactions
Spliceozymes and the CAT pre-mRNA substrate were generated by run-off in vitro transcription from PCR products with T7 RNA polymerase, essentially as described [22] . The template for PCR of the spliceozyme, and of CAT pre-mRNA, was the plasmid clone pUCSz2_100-SiC10. The PCR of the spliceozyme used 59primers that contained the T7 RNA polymerase promoter and truncated 59-recognition sequences, and 39-primers that truncated the spliceozyme 39 
In vitro reactions
In vitro reactions were done essentially as described [22] . The final spliceozyme concentration was 1 mM or 100 nM, as noted, and CAT pre-mRNA substrate concentrations were 100 nM. Reactions were incubated in 5 mM MgCl 2 , 135 mM KCl, 50 mM MOPS/NaOH pH 7.0, 20 mM GTP, and 2 mM spermidine, at 37uC, in reaction volumes of 20 mL. Spliceozyme and substrate were pre-incubated separately in the reaction buffer for 10 minutes at 37uC before combining the solutions to start the reaction. Samples were taken in 2 mL aliquots after reaction times of 0, 1, 2, 5, 10, 20, 30, and 60 minutes. In vitro reaction products were separated on 7 M urea 6% PAGE and visualized by phosphoimaging. Bands were quantified on a phosphorimager (PMI, Bio-Rad) using the software Quantity One. The background was substracted using the rolling disk method, with two different methods to minimize artifacts. To quantify substrate and products, disk sizes were set such that the background-signal flanking each peak was contacted by the background subtraction line. To quantify the signal of the 59-exon side product, the disk size was chosen larger such that the peaks of substrate and product were not separated. The signal strengths were then normalized for two factors: to take into account that each internally labeled fragment contained a different number of A's, the signal strengths of each fragment were divided by their number of A's. To account for gel loading errors, signals were also normalized for the total radioactivity per lane. This resulted in the molar fraction of substrate converted to product, which was reported in the figures. The time courses of the signal intensities were fitted for least-squares differences in Microsoft Excel using the Solver tool. All signals of products were fit well by single-exponential functions; all signals of substrates required double-exponential functions.
Activity measurements in E.coli
Fresh overnight cultures of E. coli cells in LB medium containing 100 mg/mL ampicillin were diluted with LB medium to an A 600 of 0.025, induced with IPTG at a final concentration of 1 mM, and shaken at 37uC for 1 hour. Growth was then measured on LBagar plates instead of LB liquid culture because plates prevented single false-positive clones from overtaking the population [21] . Hundred mL of each IPTG-induced liquid culture were plated on one LB agar plate containing 100 mg/mL ampicillin. The same volume from the same cell suspension was plated on one LB agar plate containing the noted concentration of chloramphenicol and 1 mM IPTG. Plates were incubated at 37uC for 16 hours. Each plate was washed with 1.6 mL 1xPBS, and the A600 of each cell suspension was measured. The A 600 obtained for LB-ampicillin plates was divided by the A 600 from the corresponding LBchloramphenicol plates to normalize the growth in the presence of chloramphenicol for the number of viable bacteria. The two introns used for the first activity measurements in E. coli cells ( Figure 4B) were two clones resulting from the selection with 28 random nucleotides in the internal sequence of the intron. These two N 28 sequences were 59-GGCCACAGGCCCCGCGTCGCG-GTGGGGC-39 (clone 64-SiC2) and 59-ATTCTTGATACTT-TATTATTCAATTGTT-39 (clone 64-SiC3).
RT-PCR, sequence analysis, RT-qPCR, and plasmid yield
For the sequence analysis of in vitro splicing reactions, RNA was obtained by ethanol preparation after 60 minutes of incubation. For the analysis of in vivo splicing reactions, total RNA was isolated from logarithmically growing E. coli cultures using the Nucleospin RNA II kit (Machery-Nagel). In reaction volumes of 20 mL, RNA from the in vitro reaction containing 2 pmol CAT pre-mRNA and 20 pmol spliceozyme, or 3.2 mg of total RNA were incubated with 200 units of Superscript III reverse transcriptase (Invitrogen), for 60 minutes at 55uC, using the primer 59-ccgtaacacgccacatc-39 complementary to the CAT 39 exon. DNA sequences were amplified by PCR with primers 59cggcctttattcacattct-39 and 59-gtgtagaaactgccggaa-39. A nested, second PCR introduced restriction sites EcoRI and BamHI using primers 59-gcatgaattccgcctgatgaatgctcat-39 and 59-gcatggatccgtattcactccagagcgat-39 (restriction sites underlined). The products were cloned into plasmid pUC19b [21] and 10 clones were sequenced for each reaction.
To quantify the amount of CAT RNA 39-exons in total RNA, reverse transcription products (see above) corresponding to 20 pg of total RNA were amplified in a volume of 10 mL using the two primers 59-CCGTAACACGCCACATC-39 and 59-TGTTA-CACCGTTTTCCATGAG-39, both of which anneal in the 39exon of the used CAT pre-mRNA sequence. The qPCR reactions were incubated with the Applied Biosystems qPCR master mix on the Fast 7500 RT-qPCR machine (Applied Biosystems), as described previously [21] . Only a single PCR product was observed in melting profiles.
Plasmid yields were determined by isolating plasmids from 2 mL of logarithmically growing E. coli cultures with an OD 600 of 0.5, using the Nucleospin plasmid kit (Macherey Nagel). This was in the linear range of the assay, in which the plasmid yield from 2 mL bacterial culture correlated linearly with OD 600 values in the range from 0.0 to 1.0 (data not shown). Figure S1 Fraction of 59-exon side products during the in vitro reaction of the spliceozyme. The fraction is shown as the molar fraction of the CAT pre-mRNA at the start of the reaction (see Figure 2 ). (A) Influence of spliceozyme concentration and design at the ribozyme 59-terminus. At the concentration of 1 mM (filled symbols) the 59-exon was released 4-fold faster than at 100 nM (empty symbols). When the spliceozyme 59-terminus ended in the P1 helix (squares) the release of the 59-exon was 2fold faster than when the spliceozyme 59-terminus ended in the P1 extension (circles) or the 59-duplex (triangles). (B) Influence of the length of the P9.2 duplex at the ribozyme 39-terminus, with a 59terminal P1 duplex. The lengths of the P9.2 helix had no or a minor influence on the release of the 59-exon, as judged by the comparison between P9.2 helices with a length of 9 base pairs (empty squares), 8 base pairs (empty diamonds), 7 base pairs (empty circles), 6 base pairs (empty triangles), and 5 base pairs (filled squares). Error bars show standard deviations from the average of triplicate experiments. (PDF)
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